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Abstract Chromosomal disorders, of which Down syndrome
is the most common, can cause multi-domain disability. In
addition, compared to the general population, there is a higher
frequency of death before the age of five. In many settings,
large gaps in data availability have hampered policy-making,
programme priorities and resource allocation for these impor-
tant conditions. We have developed methods, which over-
come this lack of data and allow estimation of the burden of
affected pregnancies and their outcomes in different settings
worldwide. For example, the methods include a simple equa-
tion relating the percentage of mothers 35 and over to Down
syndrome birth prevalence. The results obtained provide a
starting point for consideration of services that can be imple-
mented for the care and prevention of these disorders.
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Abbreviations
EUROCAT European Surveillance of Congenital
Anomalies
ICBDSR International Clearinghouse for Birth Defects
Surveillance and Research
MGDb Modell Global Database of Congenital
Disorders
TOP Termination of pregnancy
UN WPP United Nations World Population Prospects
Introduction
Chromosomal disorders are caused by changes occurring in
either chromosome number or structure usually during the for-
mation of gametes or soon after fertilisation. These changes can
affect the autosomes or the sex chromosomes (XX in females,
XY in males), with chromosomal disorders divided into the two
corresponding groups. Most autosomal disorders cause death
before the age of 5 years or multi-domain disability. However,
the availability of appropriate medical care in high-income set-
tings means that there are fewer deaths in those with Down
syndrome before the age of five (Glasson et al. 2016; Kucik
et al. 2013; Wu and Morris 2013). Disorders of the sex chro-
mosomes have a lesser effect on survival but can cause infertil-
ity, congenital malformations such as congenital heart disease
in Turner syndrome (Pinsker 2012), as well as having
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neurodevelopmental and psychological impacts (Bojesen and
Gravholt 2007; Pinsker 2012; Tartaglia et al. 2015) (Table 1).
Chromosomal disorders can occur in any pregnancy (most arise
sporadically), but the risk of having a pregnancy affected by
Down syndrome and trisomies T13 and T18 is known to in-
crease with maternal age (Hassold et al. 1996; Hassold and
Hunt 2009; Hook et al. 1983).
The Modell Global Database of Congenital Disorders
(MGDb) uses a set of defined methods to relate demographic
data to the known birth prevalence of selected congenital dis-
orders, to generate estimates relevant to public health, policy
making and clinical practice (Blencowe et al. 2016; Moorthie
et al. 2016). This paper, the fourth in a supplement on estima-
tion of congenital disorders, describes the methods used in
MGDb to estimate the baseline birth prevalence and pregnan-
cy outcomes of the chromosomal disorders listed in Table 1.
Balanced structural rearrangements and sex chromosome dis-
orders that cause minimal health problems (e.g. XYY and
XXX) are not included. This paper will be of interest to those
seeking to estimate the burden of chromosomal disorders and
potential effect of interventions in settings with limited data
including policy and programme planners.
Overview of methodology
The incidence of most congenital disorders, including Down
syndrome, is usually expressed as birth prevalence. This is for
practical purposes, as it is recognised that many affected embry-
os fail to implant or miscarry in early pregnancy, hence never
come to the attention of health services. We too have followed
this convention and equated birth prevalence with incidence.
The objective ofMGDb is to estimate numbers of births affected
by one or more congenital disorders and outcomes (live birth,
stillbirth or termination of pregnancy (TOP)) in the no-care
situation and with current care. The starting point for this is
baseline prevalence (i.e. live birth and stillbirth) in the absence
of care. MGDb provides epidemiological estimates relating to
birth prevalence, pregnancy outcomes, survival and effect of
interventions. These estimates are not definitive and require re-
finement, but can be used by those working in public health or
by policy makers as a starting point to assess service needs and
policy gaps in settings with little or no data.
To estimate the potential live birth prevalence of chromo-
somal disorders for different populations, we used a step-wise
approach:
Step 1: Estimation of the expected prevalence of Down
syndrome among live births in the absence of any interven-
tion using the established relationship with maternal age
Step 2: Estimation of the birth prevalence of other chro-
mosomal disorders and foetal deaths
Step 3: Estimation of the overall baseline birth prevalence of
chromosomal disorders in the absence of any intervention
Step 4: Estimation of actual birth prevalence based on the
availability and estimated access to prenatal diagnosis and
termination of pregnancy (TOP) for foetal impairment
Step 5: Comparisons of estimates with registry data
Step 1: Expected prevalence of Down syndrome
among live births in the absence of intervention
Maternal age-related rates for live births with Down
syndrome
The live birth prevalence of chromosomal disorders in the
absence of intervention was originally described in
Table 1 Chromosomal disorders included in MGDb. A small minority
of those with chromosomal disorders is mosaics (have both normal and
abnormal cells) and this causes a less severe disorder. InMGDb, Edwards
syndrome (+18) and Patau syndrome (+13) are treated together because
their outcomes are very similar. Rare autosomal disorders include
triploidy, other trisomies, unbalanced structural rearrangements,
markers, and microdeletions
Group Disorder Maternal age-
related?
% of cases that
have associated
malformations
Other clinical features Source of prevalence data
Autosomal disorders Down syndrome (T21) Yes 40–50 Learning difficulties,
reduced immunity,
premature ageing
Hecht and Hook (1996),
Morris et al. (2014)
Edwards syndrome (T18) Yes 100 Very severe developmental
disorders resulting in
early death in infancy
Savva et al. (2010)
Patau syndrome (T13)
Rare autosomal disorders Some Most Diverse group, severe
learning difficulties,
other problems
Wellesley et al. (2012)
Sex chromosome disorders Turner syndrome (45,X) No 30 Failure of puberty, sterility Alberman and Creasy
(1977), EUROCAT
Klinefelter syndrome (XXY) Some – Hypogonadism, sterility Bojesen et al. (2003)
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populations mainly of northern European origin (Hecht and
Hook 1996; Hook and Hamerton 1977). These studies
showed that the birth prevalence of Down syndrome and tri-
somies T13 and T18 is related to maternal age. Klinefelter
syndrome was also shown to have a weak maternal age rela-
tionship, while the birth prevalence of Turner syndrome
(45,X) and most other chromosomal disorders are approxi-
mately constant across these populations.
Studies have described ethnic differences in Down syndrome
birth prevalence; however, it is uncertain if these differences are
due to underlying biological factors or as a result of differential
use of screening services or due to differential ascertainment
(Bishop et al. 1997; Forrester and Merz 2003; Khoshnood
et al. 2000). In the absence of studies that provide evidence to
support significant differences in these rates between population
groups, or any effect of environmental or other genetic factors,
we have assumed that the observations relating to risk in the
initial studies are generalizable to all populations globally.
The relationship between maternal age and risk of a Down
syndrome-affected live birth is employed in counselling preg-
nant women in relation to their risk of an affected birth (Bray
et al. 1998; Cuckle et al. 1987; Hecht and Hook 1996).
However, the data used to construct the initial curve were
collected between 1966 and 1980, when the proportion of
older mothers was at its lowest in the relevant populations,
and confidence intervals for the oldest groups were conse-
quently very wide. Subsequent studies have included more
data points (Ferguson-Smith and Yates 1984; Morris et al.
2002, 2005). We therefore combined the data of Hecht and
Hook (1996) and Morris et al. (2002) in order to maximise the
number of older mothers included (see ESM 1: Table 1 online
resources). We used these data to produce a curve (ESM 1:
Fig. 1 online resources) to estimate Down syndrome risk by 5-
year age groups (Table 2). Five-year age groups were
employed in order to relate to demographic data which are
presented using these age intervals. The resulting rates were
very close to those reported by Wu and Morris (2013) and
were used to develop an equation-based method to estimate
Down syndrome live birth prevalence.
Relating risk to maternal age distribution
The proportion of all births to older women changes with
population age distribution, social changes and utilisation of
family planning (ESM 1: Fig. 2 online resources). Therefore,
the live birth prevalence of maternal age-related disorders dif-
fers between populations and over time. In theory, Down syn-
drome live birth prevalence can be estimated for every country
by applying the risks in Table 2 to the UNWPP estimates of
maternal age distribution. However, there are possible sources
of error in this approach.
Inaccuracy in age reporting is common, particularly in
lower-income settings, among less educated and older groups
and among women. This can lead to ‘age heaping’, which is
the tendency to estimate age up to the nearest figures ending in
0 or 5 (UN Demographic Yearbook special issue on age
heaping, 2017). Age heaping can be quantified using
Whipple’s index, which provides a means of assessing the
reliability of age data (Shryock et al. 1976). Index scores range
between 100 and 500; a high score (generally above 125)
indicates lower quality data. A review of Whipple’s index
for 1985 to 2003 in the United Nations Demographic
Yearbook (UNDY) special issue on age heaping (UN
Demographic Yearbook special issue on age heaping 2017)
shows that only population age data from the European and
Western Pacific regions are truly reliable, as these index scores
are close to 100 (online resources ESM 1: Table 2). This is
likely to apply even more to maternal age data, especially for
older age groups, as age heaping is most marked in the oldest
age group. Therefore, only maternal age data for populations
with a Whipple’s index of 105–110 can be used to support
accurate calculation of Down syndrome birth prevalence
using the 5-year maternal age groups in Table 2.
If age heaping is not taken into account, it can lead to
inaccuracies in the estimation process and overestimation of
the live birth prevalence of Down syndrome. We sought to
reduce the effect of heaping by developing a formula to de-
scribe the relationship between the percentage of mothers
aged ≥ 35 and Down syndrome live births. This was
Table 2 Risk of a Down
syndrome live birth by 5-year
maternal age intervals. (based on
Hecht and Hook (1996), Morris
et al. (2002))
Maternal age
group
Down syndrome
live births
Total live
births
Down syndrome
live births/1000
Lower
95% CI
Upper
95% CI
15–19 71 124,562 0.61 0.54 0.67
20–24 387 541,511 0.71 0.67 0.75
25–29 533 585,770 0.87 0.83 0.90
30–34 390 260,378 1.46 1.40 1.51
35–39 380 84,373 4.58 4.42 4.74
40–44 276 17,655 15.71 14.98 16.44
45–49 46 893 33.50 28.54 38.46
Total 2085 1,615,142 1.52
Total 15–34 1381 1,5122,21 0.913
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undertaken in two steps. Firstly, we used the rates for Down
syndrome birth prevalence in Table 2 along with country-
specific age distribution to estimate country-specific birth
prevalence by five-year intervals. This was done only using
age distribution data from countries with little age heaping, as
assessed by their Whipple’s index. Fifty-four countries had
evidence of reliable demographic age data. These data includ-
ed countries from western Europe with the highest estimated
proportion of mothers ≥ 35 and eastern Europe where the
proportion of mothers ≥ 35 is the lowest globally. We then
plotted the calculated Down syndrome birth prevalence by
country against total WPP births to mothers’ ≥ 35, in these
countries, the rationale being that the larger ≥ 35 age group
can easily accommodate inaccuracies in the reporting of ma-
ternal age at the oldest groups. Figure 1 shows a linear rela-
tionship between the percentage of mothers aged ≥ 35 and
Down syndrome live birth prevalence. This empirical relation-
ship can be describedmathematically by the following formula:
y ¼ mxþ b
where:
y down syndrome potential live births/1000
m the slope of the line (0.067)
x percentage of mothers ≥ 35 × 0.067
b the intercept (0.834)
A comparison of estimated potential live birth prevalence,
applying the risks to the five-year bands, compared to the
formula above using WPP 2015 maternal age data from
1950 to 2015, can be found in the online resources for three
countries (Online Figs. 3, 4 and 5)—United Kingdom, Nigeria
and Iran. Identical results are obtained for the UK using both
methods, which has a low Whipple’s index. However, the
former approach produces higher estimates for countries with
a high Whipple’s index (Iran and Nigeria). To avoid overesti-
mation and for the sake of consistency, we use the formula
above to estimate Down syndrome potential live birth preva-
lence in any population, including those for which maternal
age data are highly reliable. Maternal age distribution data
were obtained from the United Nations World Populations
Prospects - UNWPP (United Nations Population Division
2015)
Step 2: Estimating potential live birth rates of other
chromosomal disorders and foetal deaths
In MGDb, estimates for T13 and T18 are grouped together as
they have similar outcomes. The birth prevalence of these
disorders is also maternal age-related, with a joint live birth
prevalence approximately 19.5% of that of Down syndrome
(Savva et al. 2010). We used this figure to estimate the com-
bined potential live birth prevalence of these two conditions.
Rates for rare chromosomal disorders are also based on
data available in the literature. Using EUROCAT data,
Wellesley et al. (2012) found a total birth prevalence of
0.74/1000 for ‘rare chromosomal disorders’. However, the
study indicates a likely 25% foetal death rate had prenatal
diagnosis not been available. Taking this into considerations
gives a baseline live birth prevalence of around 0.55/1000.
The baseline live birth prevalence of Turner syndrome
(45,X) used in MGDb was derived from an average of
country-specific rates using publicly accessible EUROCAT
data for the years 2000–2009. Data included in the analysis
was from registries that submit raw data and from countries
where TOP is legal and reported (Ireland, Malta and Poland
were excluded). Average EUROCAT data indicate that the
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Fig. 1 Relationship between
percentage of mothers ≥ 35 plus
and Down syndrome potential
live birth prevalence. Live birth
prevalence was estimated using
the full range of risks in Table 2
for 54 high-income and eastern
European countries with reliable
demographic data. The selection
covers a wide spread of rates be-
cause the proportion of older
mothers is high in high-income
countries but low in eastern
Europe. Calculations are for
2005–2009, but results are similar
for any time interval. Coefficient
of correlation = 0.9944
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potential live birth prevalence of Turner syndrome (45,X) is
approximately 0.175/1000.
The birth prevalence of Klinefelter syndrome (XXY) is
weakly related to maternal age because around half of the
responsible non-disjunctions are of paternal origin (Bojesen
et al. 2003; Carothers and Filippi 1988; Ferguson-Smith and
Yates 1984). However, we have not used a maternal age rela-
tionship to estimate birth prevalence in MGDb, but used the
average potential live birth prevalence of 0.703/1000 reported
by Morris et al. (2008)
Estimating foetal death rates
Most publications report live birth prevalence of chromosomal
disorders because they aim to provide precise risks for genetic
counselling. However, to assess their public health signifi-
cance, it is necessary to include stillbirths and to allow for the
effects of prenatal diagnosis in countries where pregnancy ter-
mination is legal.We use foetal death, defined as losses in utero
after 20 weeks as a proxy for stillbirths. To obtain potential total
birth prevalence, estimates for foetal deaths were added to the
estimated live birth rates obtained using the formula.
Rates for pregnancy losses have been reported and shown
to differ with stage of gestation and the condition (Morris and
Savva 2008; Morris and Wald 1999). In MGDb, we use rates
for foetal deaths i.e. from 20 weeks of pregnancy onwards.
There are differences in foetal death estimates, and this is
particularly marked for Down syndrome, such as 5% by
Halliday et al. (1995) and 12% by Morris and Wald (1999).
We have used the conservative figure of 5% of total births
(equivalent to 5.3% of live births) until more data are avail-
able. Table 3 summarises potential foetal death rates in the
absence of any intervention, by main disorder group along
with sources of data.
These calculations can be used to produce baseline birth
prevalences for any population. Although a large proportion
of miscarriages (losses before 20 weeks) are associated with
chromosomal aneuploidy and risk of miscarriage accordingly
rises with maternal age (Alberman and Creasy 1977), miscar-
riage is not considered here. Figure 2 shows estimates of base-
line birth prevalence of chromosomal disorders by WHO re-
gion for 2010, calculated using this method.
Step 3: Estimation of the overall baseline birth
prevalence of chromosomal disorders
The overall prevalence is calculated by summing the baseline
birth prevalence, including both live births and foetal deaths of
all included chromosomal disorders from steps 1 and 2. This
approach has the advantage of providing a starting point from
which the impact of interventions can be examined and
evaluated.
Step 4: Estimation of actual birth prevalence
The results from step 3 apply directly for countries where
termination of pregnancy for foetal impairment is illegal, but
must be adjusted to allow for the effects of prenatal diagnosis
in countries where termination is legal.
Adjusting for factors that impact on pregnancy outcomes
Most countries with appropriate resources where TOP for foe-
tal impairment is legal have developed antenatal screening
programmes specifically targeted at Down syndrome. These
programmes identify pregnancies with an increased likelihood
of foetal anomalies and offer an option for early diagnosis.
Although targeted specifically at Down syndrome, antenatal
screening and diagnosis programmes are likely to identify
other chromosomal anomalies, including trisomies 13 and
Table 3 Potential percentage foetal deaths in the absence of any intervention by chromosomal disorder
Diagnosis Potential live births/1000 Foetal deaths, %
of live births
Foetal deaths, %
of total birthsa
Source used for foetal
death rate
Down syndrome Estimated using maternal age 5.3 5 Morris et al. (1999)
Other trisomies Estimated as 19.5% of Down
syndrome prevalence
122 55 Morris et al. (2008)
Other autosomal disorders 0.55 28 25 Wellesley et al. (2012)
Turner syndrome 0.175 27 21 EUROCAT averageb
Klinefelter syndrome 0.703 3.0 2.9 EUROCAT averageb
Note: When only information on live birth prevalence is available, the figures in the third column can be used to calculate foetal deaths. When only
information on total birth prevalence is available, the figures in the fourth column can be used to calculate foetal deaths
a Total births = live births plus stillbirths
b Data source: EUROCAT website. Data from the registries that submit raw, unaggregated data were included in the analysis. Includes only data from
countries where TOP is legal and reported (Ireland, Malta and Poland were excluded)
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18 and 45,X. The identification of individuals with other chro-
mosomal anomalies is usually made later in life, following
other diagnostic investigations. Prenatal diagnosis may allow
planning and preparation for an affected family or, in places
where it is legal and acceptable, may lead to a choice of preg-
nancy termination.
Techniques and policies for prenatal diagnosis of chromo-
somal disorders have evolved greatly over the last half-
century impacting on the proportion of cases detected and
their acceptability to pregnant women and their partners. For
example, the development of combined screening has led to a
policy in many countries of offering risk information and
screening to all pregnant women, followed by definitive diag-
nosis to those who have been identified as at high risk.
Umbrella registries (ICBDSR and EUROCAT) have re-
corded almost the entire evolution of the population impact
of screening and diagnosis for chromosomal disorders in high-
income settings. Consequently, country-specific data on ter-
mination of pregnancy from umbrella registries are used for
these estimates when available. Otherwise, we have used pub-
licly available data from EUROCAT to estimate the average
proportions of pregnancies terminated by diagnosis by 5-year
interval, in participating countries where termination of preg-
nancy is legal and reported (Table 4). Information relating to
legality of termination of pregnancy (TOP) for fetal impair-
ment was obtained from the UN (United Nations 2014).
We compared these rates with those of the UK National
Down Syndrome Cytogenetic Register (National Down
Syndrome Cytogenetic Register (NDSCR) (2017)) in order
to examine the degree to which they reflect the informed
choices of pregnant women. NDSCR data for England and
Wales in 2009 show that the great majority of women are
informed of the availability of testing in time for the option
of prenatal diagnosis; around 70% request screening for chro-
mosomal disorders and over 95% of those with a definitive
diagnosis of a severe disorder choose to terminate the preg-
nancy (Springett and Morris 2010; Springett et al. 2014). The
resulting 60% termination rate calculated fromNDSCR data is
close to the EUROCAT average (58.7%).
Due to the absence of readily accessible observational data
on the availability and utilisation of prenatal diagnosis, we
have assumed that it will be available in those countries where
TOP is legal and access to care will impact utilisation. In
MGDb, we have used the EUROCAT average rates for set-
tings that have a policy of universal screening. In settings
where termination of pregnancy is legal but there is no evi-
dence of a universal screening policy and no available data on
termination rates, we have assumed testing is offered only to
high-risk groups. In these settings, we have used a rate which
is 50% of the EUROCAT average. We have assumed that all
women worldwide with access to screening and TOP will act
in the same way in terms of uptake of this service. It is
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disorders by WHO region in
2010–2014. AFR: African, AMR:
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Western Europe
Table 4 Average percentage rates for termination of pregnancy for chromosomal disorders for 16 countries where termination for foetal impairment is
legal and reported. Data source: EUROCATwebsite. Data from the registries that submit raw, unaggregated data were included in the analysis. Includes
only data from countries where TOP is legal and reported (Ireland, Malta and Poland were excluded)
Disorder group 1980–1984 1985–1989 1990–1994 1995–1999 2000–2004 2005–2009
Down syndrome 4.3 14.7 28.3 45.2 52.9 58.7
Other trisomies 8.2 39.8 57.1 67.7 75.7 81.4
Rare disorders 9.3 23.7 54.6 47.8 41.7 42.1
Turner syndrome 32.9 45.1 58.2 64.9 65.7 69.9
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assumed that no widespread screening for chromosomal dis-
orders or terminations takes place in countries where termina-
tion of pregnancy for foetal impairment is illegal. This is likely
to lead to slight overestimation of actual live birth prevalence,
as a minority of couples can usually access such services, for
example as in the case of Brazil (Diniz and Medeiros 2010;
Horovitz et al. 2013).
Step 5: Comparison of estimates with registry data
for Down syndrome
Direct comparisons between estimates and reported data from
low-middle-income settings are difficult to interpret due to
weaknesses in reported data. However, we can compare dif-
ferences between estimated and reported baseline prevalence
rates for countries contributing to EUROCAT (Fig. 3) and
ICBDSR (Fig. 4). Rates are comparable for 10 of the 22 coun-
tries contributing to EUROCAT. For the remaining 12 coun-
tries, the observed rate is 20–50% lower than predicted. There
is recognised under-ascertainment in the four countries with
the widest difference (starred)—with under-ascertainment
demonstrated in Italy, Netherlands (de Graaf et al. 2011) and
Portugal (Leoncini et al. 2010) and inevitable for Poland be-
cause terminations are not reported. Similarly, there is good
agreement for six international registries contributing to
ICBDSR. Discrepancies are evident for countries not
reporting TOP (South Africa, British Colombia, Japan and
New Zealand). The lower estimated than reported rate for
Chile suggests either unreliable maternal age data or over-
diagnosis of Down syndrome. Wide discrepancies for
Mexico, Costa Rica and Cuba suggest substantial under-
ascertainment.
Based on the examples above, under-ascertainment would
seem to explain much of the difference between estimated
Down syndrome birth prevalence and reported rates from reg-
istry data in high-income settings. Under-ascertainment might
be of births, foetal deaths, terminations of pregnancy or a
combination of all three. Under-ascertainment of foetal death
(current estimated total = 5% of continuing pregnancies)
would not greatly affect the reported birth prevalence of
Down syndrome. Under-ascertainment seems more likely for
terminations than for live births, particularly where there is
widespread use of private maternity services or termination
of pregnancy is illegal or a highly politicised issue. Under-
ascertainment of terminations for other trisomies has been
documented in the USA (Crider et al. 2008). Selective
under-ascertainment of terminations may be suspected when
both (a) the reported total birth prevalence is substantially
lower than predicted and (b) the reported proportion of termi-
nations is substantially lower than expectation.
Discussion
Strengths of method
Large gaps in data availability regarding chromosomal disor-
ders have hampered policy-making, programme priorities and
resource allocation for these important conditions. The
methods proposed above allow an estimate of the burden of
affected pregnancies and their outcomes from all settings,
even those with sparse data. These estimates provide a starting
point for consideration of services that can be implemented to
address the burden of these disorders. The strengths of the
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Fig. 3 Comparison of estimated potential Down syndrome live births/
1000 with observed potential live births calculated from EUROCAT reg-
istry data for 2000–2009. In order to make the comparison, EUROCAT
total Down syndrome birth prevalence was converted to potential live
birth prevalence, by deducting 5% to allow for potential foetal deaths,
and deducting 30% from reported terminations to allow for spontaneous
losses had these pregnancies continued. Countries ranked in descending
order of discrepancy. *Countries with the widest discrepancy
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method lie in the fact that it provides a relatively simple pro-
cess to estimate the birth prevalence and pregnancy outcomes
of chromosomal disorders. The availability of estimates of
maternal age distribution from UNWPP makes it possible to
develop country-specific estimates of the baseline birth prev-
alence of Down syndrome and other maternal age-related
chromosomal disorders, regardless of resource level.
Estimates can be made for other chromosomal disorders using
rates either from the literature or through analysis of data
available from EUROCAT—which is an established surveil-
lance network.
When data is already collected on birth prevalence of these
conditions by population-based registries, the method outlined
here provides an independent means to assess ascertainment.
As mentioned previously, these methods do not allow defini-
tive estimates, but provide order to magnitude estimates that
can be used by public health and policy makers to assess
burden of disease and evaluate service needs. The steps taken
and assumptions made allow this method to be applied across
global populations which is an advantage, and comparison
with observational data shows that rates are comparable in
many cases. Where there are discrepancies, these can, to a
large degree, be explained by under-ascertainment.
However, the assumptions made in this process can add to-
wards uncertainty around the estimates, and these are
discussed below.
Limitations of model
Potential limitations of the estimation process include the use
of five-year maternal age bands. Curves to estimate Down
syndrome risk are usually constructed using one-year age
bands. Given the strong relationship between maternal age
and risk, this allows more accurate risk assessment especially
for use in a counselling setting. In order to relate to
demographic data, which is usually presented in 5-year bands,
we have used 5-year age groups to relate risk to maternal age.
This could introduce uncertainty at two levels. Firstly, we
have amalgamated two data sets to produce a risk curve. The
data of Hecht and Hook (1996) were collected between 1966
and 1990 whereas that of Morris et al.(2002) were for the time
period 1990–1998. As the data are from different time periods,
there is a possibility that differences in maternal age structure
between these periods impact on calculated one-year risk.
However, this will only be the case if there is temporal differ-
ence between the maternal age relationship, which we think is
unlikely. Secondly, the risks within each 5-year age band are,
in essence, an average across this wider age group, which is
likely to be influenced by the exact distribution of risk across
these age bands.
We have assumed that risks are constant over time and that
there are no ethnic differences. Although studies have been
published examining ethnic differences in prevalence of
Down syndrome, it is unclear at this time whether this is as
a result of underlying biological factors or as a result of dif-
ferential health care utilisation or social factors.
Another potential limitation with the estimation process
includes the assumption that historical high-income country
setting rates apply to all countries with a lack of data, and
where there is access to termination of pregnancy, women
will choose in a manner comparable to those of their
European counterparts. This can contribute to uncertainty,
firstly, as although current surveillance systems in these
countries are robust, individual registries can differ in as-
certainment due to a number of factors (e.g. resources,
extent and mode of access to records etc.) as well as at
the proportion of the total population they cover. This can
lead to differences between countries in reported rates, es-
pecially for outcomes that do not end in an affected birth
such as foetal death/stillbirth and termination of pregnancy.
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Secondly, there is a high rate of TOP for Down syndrome,
other autosomal disorders and Turner syndrome in high-
income countries where termination is legal. This assump-
tion may therefore overestimate TOPs in other settings and
therefore underestimate the number of foetal deaths and
live births. Termination may be under-reported from coun-
tries where termination for foetal impairment is legal, but
the issue is highly politicised. The extent to which termi-
nation reflects, informed parental choice has not been suf-
ficiently investigated. Estimation of termination of pregnan-
cy is based on EUROCAT and ICBDSR registry data.
However, there may be considerable under-ascertainment
in some countries (Leoncini et al. 2010). When this is the
case, live birth prevalence and mortality due to the disorder
are overestimated.
Although it is desirable to have as accurate as possible
estimates for public health and service planning purposes,
often this must be balanced against the feasibility of obtaining
such data. Our aim has been to create a simple method that can
utilise available data to start assessing service needs for those
with chromosomal disorders.
Conclusion
Our aim is to describe a simple method to estimate the birth
prevalence of chromosomal disorders summarised in
Table 2. The formula-based method used for estimates of
Down syndrome birth prevalence derived from the propor-
tion of mothers’ ≥ 35 is a useful tool for public health
purposes. The method can be applied for any country, at
any time period, and can be employed to assess ascertain-
ment in local registries. In fact, calculation using maternal
age distribution has already been suggested for assessing
ascertainment of chromosomal disorders in registries
(Leoncini et al. 2010) and is used by EUROCAT as a data
quality indicator (Loane et al. 2011, 2013).
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